药物导致肝损伤是药物研发失败和上市药退市的一个主要原因。药物导致肝损伤的频发跟肝生理功能密切相关,因为大部分药物分子在体内的消除依赖于药物代谢或胆汁排泄的肝清除。虽然不少发病机制已有广泛的研究,但是大部分与药物导致肝损伤相关的机制仍然未明确。从这个意义上讲,代谢组学将成为研究药物导致肝损伤强有力的手段以有助于更好地了解其机制并进行相关生物标志物的鉴定。 Drug-induced liver damage is one of the major reasons for the failure of drug development and the delisting of listed drugs. The frequency of drug-induced liver damage is closely linked to the physiology of the liver, as elimination of most drug molecules in the body depends on hepatic clearance of drug metabolism or biliary excretion. Although many pathogenesis has been extensively studied, most of the mechanisms associated with drug-induced liver injury remain unclear. In this sense, metabolomics will be a powerful tool for studying drug-induced liver damage to help better understand its mechanisms and to identify related biomarkers.